** Shares of Summit Therapeutics SMMT.O up 13.41% at $31.05 before the bell
** Company and partner Akeso's 9926.HK drug ivonescimab, in combination with chemotherapy, showed "statistically significant superiority" in progression-free survival for patients with a type of lung cancer
** The companies were testing ivonescimab-chemotherapy regime in a study conducted in China, against a tislelizumab, and chemotherapy combination
** Tislelizumab is sold as Tevimbra by BeiGene 688235.SS
** The companies plan to share detailed data from the study later this year and SMMT is currently enrolling patients in a multi-regional study for the drug
** SMMT shares peaked in September 2024 after results from a study in China showed some lung cancer patients on its experimental drug had better survival rates than those on Merck's MRK.N blockbuster Keytruda
** BMO analysts say the data "further heats up competition" in the lung cancer treatment market and can put further pressure on MRK's shares
** As of last close, SMMT shares up 53.26% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.